12.04.23 -- 7 Questions To Land The Best CDMO

Drive the efficiency and resiliency of supply chains by integrating automation, AI, and effective communication, ensuring the successful distribution of lifesaving medicinal products.

Learn more about the potential of allogeneic cell therapies to combine the efficacy of personalized medicine with the scalability, accessibility, and uniformity of traditional off-the-shelf therapeutics.

The collaboration between AAV gene therapy developers and CDMOs has resulted in scalable manufacturing solutions to develop biological therapeutics poised for successful patient outcomes.

Discover how to construct an agreement between partners that favors fluid communication and alignment of business objectives — crucial for a fruitful CDMO relationship to diminish risk for both.

Finding a CDMO partner with the resources and expertise to achieve efficient and scalable manufacturing is a key step in achieving the scalable manufacture of safe, effective AAV gene therapies.

Achieving optimized, scalable suspension processes for adeno-associated virus (AAV)-based therapeutics comes with a number of technical and business challenges.

As you search for the plasmid supplier best suited to help manufacture your product, prioritize the CDMO with the plasmid production experience needed to avoid common manufacturing obstacles.

Create a simple, modular path to cGMP manufacturing that minimizes risk. Explore a strategic approach for early-stage development and how it can propel therapies to the clinic and the market.

Learn more about the complexities of gene and cell therapy manufacturing and how the right CDMO can help you fully realize the potential of your novel therapeutic.

Suparna Sanyal, Ph.D., head of viral vectors commercial development, discusses how to build a reliable, de-risked path to clinic to avoid unforeseen costs and compliance-related delays.